Novo Nordisk strikes deals worth over £4 billion ahead of semaglutide expiries
The Danish firm is buying rights to several weight-loss and cardiometabolic candidates as semaglutide patents lapse in some countries and approach expiry in Europe and the US.
TR
By Tom Reyes · Markets Editor
Oct 7 03:00 ETSource: Chemistry World
The wire
- 01Novo Nordisk has signed several deals collectively valued at more than £4 billion for rights to weight-loss and cardiometabolic disease treatments.
- 02The buying spree is read as an effort to offset revenue loss once semaglutide, the active ingredient in Wegovy and Ozempic, faces generic competition in major markets.
- 03Semaglutide patents have already expired in several countries and are set to lapse in Europe and the US over the next few years; individual deal terms and candidates were not detailed.
From the source
Read at chemistryworld.comNovo goes on deal spree amid semaglutide patent expiries | Business
Source: © Kristian Tuxen Ladegaard Berg/SOPA Images/LightRocket/Getty Images
